GlobeNewswire·Jun 3, 2026, 4:01 PM ET

Jade Biosciences Announces Proposed Underwritten Public Offering

Jade Biosciences, Inc. (NASDAQ: JBIO) announced an intent to sell common stock or pre-funded warrants in a proposed underwritten public offering subject to market conditions.
The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of the offered securities at the public offering price less discounts.
Jade plans to use net proceeds from the offering along with existing cash to fund clinical trials, preclinical studies, manufacturing, research, development, capital expenditures, working capital, and general corporate purposes.
Jefferies, TD Cowen, UBS Investment Bank, LifeSci Capital, and BTIG are acting as book-running managers or lead managers for the offering.
The securities are being offered under a shelf registration statement on Form S-3 declared effective by the SEC on May 15, 2026, with a preliminary prospectus supplement to be filed.
Jade's lead candidate JADE101 targets the cytokine APRIL for immunoglobulin A nephropathy, while its pipeline includes JADE201 (anti-BAFF-R) and JADE301.
Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.